|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows used in operating activities: | |||||
| Net loss | |||||
| Adjustments for non-cash items: | |||||
| Unrealized gain on changes in fair value of biological assets | |||||
| Realized fair value adjustments on inventory sold or impaired | |||||
| Fair value adjustment on warrants, investments, and accounts receivable | |||||
| Revaluation of financial instruments | |||||
| Issuance costs allocated to warrants granted | |||||
| Disposal of property, plant and equipment | |||||
| Common shares and prefunded warrants issued as share-based compensation with related party | |||||
| Discount expenses in respect of convertible debentures | |||||
| Depreciation of property, plant and equipment | |||||
| Amortization of intangible assets | |||||
| Depreciation of right of use assets | |||||
| Impairment of goodwill | |||||
| Impairment of property, plant and equipment | |||||
| Impairment of intangible assets | |||||
| Impairment of right of use assets | |||||
| Finance income, net | |||||
| Deferred tax payments (benefit), net | |||||
| Share-based payments | |||||
| Share based acquisition costs related to business combination | |||||
| Revaluation of other current receivable | |||||
| Loss from deconsolidation of Oranim | |||||
| Restructuring expenses | |||||
| Revaluation expenses of investment in affiliate | |||||
| Revaluation expenses (income) of loans receivables | |||||
| Changes in employee benefit liabilities, net | |||||
| Increase in other accounts payable and accrued expenses | |||||
| Gain from debts restructuring | |||||
| Discount expenses in respect of credit | |||||
| Total adjustments for non-cash items | |||||
| Changes in non-cash working capital: | |||||
| (Increase) decrease in trade receivables | |||||
| Decrease in other current assets | |||||
| (Increase) decrease in inventory, net of fair value adjustments | |||||
| Increase in inventory, net of fair value adjustments | |||||
| (Increase) decrease in trade payables | |||||
| (Increase) decrease in other current liabilities | |||||
| Changes in non-cash working capital | |||||
| Taxes paid | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows used in investing activities: | |||||
| Purchase of property, plant and equipment | |||||
| Proceeds from sales of property, plant and equipment | |||||
| Proceeds from loans receivable | |||||
| Purchase of intangible assets | |||||
| Acquisition of businesses, net of cash acquired | |||||
| Deconsolidation of subsidiary | |||||
| Investments in financial assets | |||||
| Proceeds from sale of investment | |||||
| Proceeds from (investment in) restricted deposits | |||||
| Investments in associates | |||||
| Investments in affiliate | |||||
| Loan granted | |||||
| Total investments in associates | |||||
| Change in restricted cash | |||||
| Net cash used in investing activities | |||||
| Cash provided by financing activities: | |||||
| Net proceeds allocated to issuance of share capital | |||||
| Net proceeds allocated to issuance of warrants measured at fair value | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds received from common shares issued upon options exercised | |||||
| Repayment of lease liability | |||||
| Proceeds received from common shares issued upon pre-funded warrants exercised | |||||
| Repayment of lease liabilities | |||||
| Payment of interest on lease liabilities | |||||
| Proceeds from loans received | |||||
| Repayment of loans | |||||
| Interest paid | |||||
| Proceeds received from discounted checks | |||||
| Net cash provided by financing activities | |||||
| Effect of foreign exchange on cash | |||||
| Change in cash | |||||
| Cash at the beginning of year | |||||
| Cash at the end of year | |||||
| Supplemental disclosure of non-cash activities: | |||||
| Right of use assets recognized with corresponding lease liabilities | |||||
| Conversion of warrant and compensation options into common shares | |||||
| Common shares issued as settlement of purchase consideration through business combination transactions | |||||
| Common shares and prefunded warrants issued as debts settlement with related party | |||||
| Issuance of convertible debentures in exchange for loans (principal and interest) received | |||||
| Common shares and warrants issued as debts settlement with related party | |||||
| Common shares issued upon exercise of pre-funded warrants | |||||
| Common shares issued upon partial conversion of convertible debentures | |||||
| Common shares issued as debt settlement | |||||
| Revaluation of put option liability versus equity |
Loading...
